Tohoku Univ. Technology ：A Diagnostic Test Enabling Precision Oncology in Head and Neck Cancer：T25-030
Predicts Therapeutic Response to ICI and Anti-EGFR Antibody Treatments
For patients with platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), first-line therapy usually involves pembrolizumab (an immune checkpoint inhibitor; ICI) with chemotherapy (5-FU plus cisplatin/carboplatin), or pembrolizumab alone for PD-L1–positive cases defined by the combined positive score (CPS). As a second-line option, cetuximab (anti-EGFR antibody) plus paclitaxel (CET+PTX) is commonly used. Our study revealed a mutually exclusive correlation between responses to first-line pembrolizumab and second-line CET+PTX. Comprehensive gene expression analyses identified key biomarkers linked to this correlation. This diagnostic approach allows prediction of each therapy’s efficacy in individual patients by measuring these biomarkers.
- 企業：Tohoku Techno Arch Co., Ltd.
- 価格：Other
